VAIA
BMRN icon

Virtus Alternative Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-140
Closed -$17K – 270
2020
Q2 		$17K Sell
140
-132
-49% -$13.1K 0.27% 81
2020
Q1 		$23K Buy
272
+157
+137% +$13.5K 0.32% 33
2019
Q4 		$10K Buy
+115
New +$8.69K 0.15% 24

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtus Alternative Investment Advisers's BMRN Position: Q3 2020 in Review

Virtus Alternative Investment Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 140 shares — an estimated $17K sold.

Virtus Alternative Investment Advisers first reported a position in BMRN in Q4 2019 and held it in 3 quarters. The position peaked at $23K in Q1 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • Virtus Alternative Investment Advisers reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 140 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $17K.
  • Virtus Alternative Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's BioMarin Pharmaceuticals position peaked at $23K in Q1 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Virtus Alternative Investment Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.